$SBFM: The new Covid variant is becoming an increa
Post# of 35216
![](/assets/46931549/no_avatar_available_thumb.jpg)
From the company:
Sunshine Biopharma’s Coronavirus Treatment Anticipated to Be Effective Against the New Variant Identified in the UK
MONTREAL, QC / ACCESSWIRE / December 22, 2020 / Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that its Anti-Coronavirus drug development program is unaffected by the recent discovery of a new strain of Coronavirus in Southern England. The new strain appears to be more easily transmissible due to a mutation in the Spike Protein, the crown-like structure on the surface of the virus which allows it to gain entry into the host cell. Sunshine Biopharma's Anti-Coronavirus compound, SBFM-PL4, acts on the Coronavirus Papain-Like Protease (PLpro) which is a non-structural protein encoded by the viral genome and synthesized by the hijacked protein synthesis machinery of the host cell. Sunshine Biopharma's SBFM-PL4 inhibits PLpro and arrests viral replication. SBFM-PL4 is expected to inhibit the PLpro of the UK variant just as well as it does the original strain since the UK strain does not show any mutations in the PLpro gene.
"Mutations in PLpro which could affect the binding of SBFM-PL4 to PLpro would have to be in the essential regions of PLpro and would likely be deleterious and produce non-viable virus particles," said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)